Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Vikas V, Dukhande"'
Publikováno v:
Heliyon, Vol 8, Iss 1, Pp e08702- (2022)
This research deals with the development of asialoglycoprotein receptors (ASGPR) directed nanoliposomes incorporating a novel BRD4 (Bromodomain-containing protein 4) protein-targeted PROTAC (Proteolysis Targeting Chimera), ARV-825 (ARV) (GALARV), and
Externí odkaz:
https://doaj.org/article/c06bc4448d5d46efbe3ca4422c9ccaf6
Autor:
Anjali Yadav, Ali Alnakhli, Hari Priya Vemana, Shraddha Bhutkar, Aaron Muth, Vikas V. Dukhande
Publikováno v:
Pharm Res
PURPOSE: Glioblastoma multiforme (GBM) is a grade IV, highly proliferative, and malignant form of brain tumor with a 5-year survival rate at ~ 5%. Current treatment strategies for GBM include surgery, radiation, and chemotherapy. Major challenges in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf335f6be8af1976b7cb3624da17f20
https://doi.org/10.1007/s11095-022-03399-4
https://doi.org/10.1007/s11095-022-03399-4
Autor:
Yige Fu, Aishwarya Saraswat, Zenghui Wei, Manas Yogendra Agrawal, Vikas V. Dukhande, Sandra E. Reznik, Ketan Patel
Publikováno v:
Pharmaceutics, Vol 13, Iss 7, p 1005 (2021)
A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a s
Externí odkaz:
https://doaj.org/article/c3edc51cc9e54d0a8d8965a4cd2cc24c
Autor:
Hari Priya Vemana, Vikas V Dukhande
Publikováno v:
Nanomedicine (Lond)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f05c876f639ff45fe8ecb2f1df875934
https://doi.org/10.2217/nnm-2021-0338
https://doi.org/10.2217/nnm-2021-0338
Autor:
Shrikant Barot, Olivia J. Stephenson, Hari Priya Vemana, Anjali Yadav, Shraddha Bhutkar, Louis D. Trombetta, Vikas V. Dukhande
Publikováno v:
Biochem Pharmacol
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths. There is an urgent need for new targets to treat HCC due to limited treatment options and drug resistance. Many cancer cells are known to have high amount of glycog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107e75cc3e1aa4cb719e5466623c8402
https://europepmc.org/articles/PMC10039449/
https://europepmc.org/articles/PMC10039449/
Publikováno v:
Nanomedicine. 16:1081-1095
Aim: To develop novel cationic liposomes as a nonviral gene delivery vector for the treatment of rare diseases, such as Lafora disease – a neurodegenerative epilepsy. Materials & methods: DLinDMA and DOTAP liposomes were formulated and characterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35cd6a19ed246a064a9b1bd59151c9b3
https://doi.org/10.2217/nnm-2020-0477
https://doi.org/10.2217/nnm-2020-0477
Publikováno v:
Pharmaceutics, Vol 11, Iss 10, p 504 (2019)
The clinical outcomes of malignant melanoma have improved with the introduction of mitogen-activated protein kinase kinase (MEK) inhibitors. However, off-target toxicities of the MEK inhibitor trametinib (TMB) often result in dose interruption and di
Externí odkaz:
https://doaj.org/article/f8c1d6f212b44efa9f9472addebc1694
Publikováno v:
The FASEB Journal. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::011909d5a857b7bb0a7dd6df071bc0f8
https://doi.org/10.1096/fasebj.2022.36.s1.r5856
https://doi.org/10.1096/fasebj.2022.36.s1.r5856
Publikováno v:
The FASEB Journal. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb29e3ac895ad6a2753599cd952de628
https://doi.org/10.1096/fasebj.2022.36.s1.r6295
https://doi.org/10.1096/fasebj.2022.36.s1.r6295